Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Intuit Inc. (INTU) Price & Performance

Heron Therapeutics IncTrade
Intuit Inc.Trade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Intuit Inc. — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while Intuit Inc. trades at $333 (market cap $91.48B). The key difference: Intuit Inc. is far larger — about 1442.7× Heron Therapeutics Inc's market cap, and Intuit Inc. pays a 1.44% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

HRTXINTU
Market Cap
$63.41M$91.48B
Sector
HealthTechnology
52-Week High
$1.49$717.21
52-Week Low
$0.32$255.07
Enterprise Value
$161.31M$89.94B
Dividend Yield
1.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

Intuit Inc.

Intuit (INTU) trades at $336.44, up 3.44% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $18.83B in 2025, with a net income margin of 20.54%, while analyst consensus is a Buy with a $401 price target. However, recent news highlights a 20% stock drop and securities fraud investigations related to TurboTax pricing issues, creating near-term uncertainty.

The outlook is mixed: strong fundamentals and AI-driven growth in financial software support upside, but legal risks and investor sentiment pressure pose challenges. Valuation metrics like a P/E of 20.4 appear reasonable if execution continues, yet volatility may persist until legal concerns resolve.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Intuit Inc.

Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.

Read more on INTU